Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy

Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy

Abstract Background Mitochondrial disease is a heterogenous group of rare, complex neurometabolic disorders. Despite their individual rarity, collectively mitochondrial diseases represent the most common cause of inherited metabolic disorders in the UK; they affect 1 in every 4300 individuals, up to...

Full description

Bibliographic Details
Main Authors: The AIMM Trial Group:, Alaa Abouhajar, Lisa Alcock, Theophile Bigirumurame, Penny Bradley, Laura Brown, Ian Campbell, Sylvia Del Din, Julie Faitg, Gavin Falkous, Gráinne S. Gorman, Rachel Lakey, Robert McFarland, Jane Newman, Lynn Rochester, Vicky Ryan, Hesther Smith, Alison Steel, Renae J. Stefanetti, Huizhong Su, Robert W. Taylor, Naomi J.P. Thomas, Helen Tuppen, Amy E. Vincent, Charlotte Warren, Gillian Watson
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Trials
Subjects:
Acipimox
Adenosine triphosphate
Mitochondrial disease
Mitochondria
Myopathy
Randomised controlled trial
Online Access:https://doi.org/10.1186/s13063-022-06544-x

Internet

https://doi.org/10.1186/s13063-022-06544-x

Similar Items